- Home
- QRVO vs NUVL Comparison
QRVO vs NUVL Comparison
Compare QRVO & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QRVO
- NUVL
- Stock Information
- Founded
- QRVO 1957
- NUVL 2017
- Country
- QRVO United States
- NUVL United States
- Employees
- QRVO N/A
- NUVL N/A
- Industry
- QRVO Semiconductors
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- QRVO Technology
- NUVL Health Care
- Exchange
- QRVO Nasdaq
- NUVL Nasdaq
- Market Cap
- QRVO 6.3B
- NUVL 6.7B
- IPO Year
- QRVO 1997
- NUVL 2021
- Fundamental
- Price
- QRVO $70.85
- NUVL $84.22
- Analyst Decision
- QRVO Hold
- NUVL Strong Buy
- Analyst Count
- QRVO 18
- NUVL 10
- Target Price
- QRVO $96.31
- NUVL $112.60
- AVG Volume (30 Days)
- QRVO 3.4M
- NUVL 429.4K
- Earning Date
- QRVO 01-29-2025
- NUVL 11-12-2024
- Dividend Yield
- QRVO N/A
- NUVL N/A
- EPS Growth
- QRVO N/A
- NUVL N/A
- EPS
- QRVO N/A
- NUVL N/A
- Revenue
- QRVO $3,948,029,000.00
- NUVL N/A
- Revenue This Year
- QRVO N/A
- NUVL N/A
- Revenue Next Year
- QRVO $4.55
- NUVL N/A
- P/E Ratio
- QRVO N/A
- NUVL N/A
- Revenue Growth
- QRVO 26.11
- NUVL N/A
- 52 Week Low
- QRVO $64.54
- NUVL $61.80
- 52 Week High
- QRVO $130.99
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- QRVO 47.96
- NUVL 32.94
- Support Level
- QRVO $68.10
- NUVL $81.37
- Resistance Level
- QRVO $70.84
- NUVL $89.31
- Average True Range (ATR)
- QRVO 2.31
- NUVL 3.37
- MACD
- QRVO 0.85
- NUVL -0.95
- Stochastic Oscillator
- QRVO 87.28
- NUVL 18.24
About QRVO Qorvo Inc.
Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of nonsmartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.